Conference Coverage

Adding foot screening to eye clinic catches diabetic neuropathy

Publish date: September 27, 2016

 

AT EASD 2016

Dr. Tesfaye reported relationships with NeuroMetrix, Impeto Medical, Eli Lilly, Pfizer, Worwag Pharma, and TRIGOcare International.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

‘Unprecedented’ Study Sheds Light on Origins of Diabetes
Type 2 Diabetes ICYMI
Insulin-dependent pilots can fly safely with glucose monitoring protocol
Type 2 Diabetes ICYMI
Dulaglutide plus insulin glargine drops HbA1c in poorly controlled type 2
Type 2 Diabetes ICYMI
‘Toe and flow’ approach to CLI management lowers amputation risk
Type 2 Diabetes ICYMI
Liraglutide cut risk of microvascular renal complications by 22% in type 2 diabetes; no eye benefit
Type 2 Diabetes ICYMI
When 1 + 1 = 3: Rational drug combinations in type 2 diabetes
Type 2 Diabetes ICYMI
Exenatide/dapagliflozin combo may be better in stubborn diabetes
Type 2 Diabetes ICYMI
Severe foot pathology predicts death in diabetes
Type 2 Diabetes ICYMI
FDA approves first-line combo therapy for type 2 diabetes
Type 2 Diabetes ICYMI
Cutting routine glucometer readings saves time and money
Type 2 Diabetes ICYMI